S&P Futures
4,026.50 +25.25 (+0.63%) Dow Futures
32,635.00 +201.00 (+0.62%) Nasdaq Futures
12,936.25 +46.00 (+0.36%) Russell 2000 Futures
1,767.30 +19.60 (+1.12%) Crude Oil
70.15 +0.89 (+1.29%) Gold
1,956.20 -27.60 (-1.39%)
Cabaletta Bio, Inc. (CABA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.47 |
| Open | 7.31 |
| Bid | 0.00 x 1000 |
| Ask | 7.56 x 800 |
| Day's Range | 7.20 - 7.58 |
| 52 Week Range | 0.59 - 12.88 |
| Volume | |
| Avg. Volume | 587,488 |
| Market Cap | 219.43M |
| Beta (5Y Monthly) | 2.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.66 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.83 |
- GlobeNewswire
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical data by the first half of 2024 – PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial
- Simply Wall St.
We're Keeping An Eye On Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, Cabaletta Bio...
- GlobeNewswire
Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET in Boston, MA. A live webcast of the presentation will be ava
